Insul-In This Together Program: Optimizing Family -based 
Interventions for Adolescents With Type 1 Diabetes and 
Their Parents  
[STUDY_ID_REMOVED] 
May 11, [ADDRESS_271374] survey and biomedical data to assess this 
program in a randomized controlled trial. 165 families (including an adolescent and 
parent) will be enrolled, complete surveys, provide biomedical data via glucose monitors 
and receive the intervention. The results of this study will inform future intervention 
redesign to provide  more judicious interventions to be disseminated across diabetes care.  
b. Objectives  
This study will evaluate the relative efficacy of each of the individual intervention components 
and also identify the mechanisms of actions ( mediators ) that are most impacted by [CONTACT_225741] -term outcomes for adolescents. This information will 
provide a more in- depth understanding of family- based program efficacy for teens with 
adolescents and provide more judicious and streamlined intervention options to be offered in 
diabetes clinics in the future.  
c. Rationale for Research in Humans  
In order to optimize family -based interventions, we need to evaluate adolescent and parent 
outcomes.  
2. STUDY PROCEDURES  
a. Procedures  
Recruitment and enrollment: Informed parental consent and adolescent assent (for ages 12 -17) or 
consent (for ages 18 -19) will be secured prior to enrollment. The recruitment phase will  
span 3 years. Participants will be recruited based on A1C results in charts or shared reports that fall within 4 weeks of baseline data collection. 
 
Randomization and assignment: After enrollment, each family will be randomly assigned to either 
the intervention condition ( 50%) or the waitlisted control condition (50%), regardless of all other 
characteristics or variables. Once randomized, instructions for scheduling and accessing the 
5/11/21  Page 2 of 11 intervention will be immediately provided to the intervention group. The intervention group will 
also be offered to participate in a voluntary monthly parent group with other parent participants to 
discuss the intervention. The waitlisted control group will receive the intervention after 6 -month 
follow -up. 
Intervention: The intervention will be conducted by [CONTACT_978] [INVESTIGATOR_225723] (clinically trained 
research staff ) via Zoom, an easy to use, accessible, and HIPAA- compliant software. Participants 
and facilitators can interact and screen - share to simultaneously view materials and videos of each 
other.  
Data collection: Data collection: Online surveys (adolescent and parent report on demographics, 
parent -adolescent relationship, diabetes, and family issues ) and glucose monitoring data will be 
captured at baseline and 3 -month (proximal endpoint ), 6-month (primary endpoint ), and 12 - 
month (distal endpoint ) follow -ups. 
Glucose monitoring data will be collected via glucose monitors that are already in use, among 
participants already using these devices at the time of enrollment, with data being shared by [CONTACT_225742]. For participants who are not already using glucose monitors at the time of 
enrollment, Libre [ADDRESS_271375] 2 weeks of data at each time point.  
A smaller set of surveys will also be conducted at approximately 2 -, 4-, and 6 -week follow -ups 
(after every 2 sessions for the intervention group and at corresponding time points for the control 
group ). Participants will be asked to report their A1Cs ( or gathered from medical records ) at 
baseline and [ADDRESS_271376] the option of not participating in conversations or exercises in the intervention modules that cause  them any discomfort. They will 
also be free to withdraw from participating in the intervention and/or overall study at any time. All 
intervention modules will be carried out by [INVESTIGATOR_124]. Wong, a licensed clinical psychologist (license 
#[ZIP_CODE]) or a clinically trained interventionist who will be consistently supervised by [INVESTIGATOR_124]. Wong. 
Survey measures are non -invasive and present minimal risk. Glucose monitors are minimally 
invasive and provide no added level of risk or discomfort beyond routine diabetes management 
tasks. A1C home test kits present minimal risk as long as participants practice safe hygiene 
practices and follow the instructions provided. Finger lancing is part of the usual care for people 
with diabetes and should not be a significant c ontributor to risks in this study. A small drop of 
blood will be obtained by [CONTACT_225743]1c. This is a standard 
method to obtain blood for routine hospi[INVESTIGATOR_31224]. Pain is common at the time of lancing. 
In about [ADDRESS_271377] for several weeks. The risk of local infection is less than 1 in 1000. Nevertheless, 
our staff (including [CONTACT_225756] who has extensive experience with diabetes devices ) will be 
available to address any potential discomfort or adverse responses to these procedures that might 
arise and will connect families with additional mental health or medical services if needed. Adolescent and caregiver participants will be advised of their rights to withdraw from the 
intervention at any time without penalty or consequence on their receipt of future health care services at Stanford University's Lucile Packard Children's Hospi[INVESTIGATOR_225724]. 
 
c. Use of Deception in the Study  
No deception will be used.  
5/11/21  Page 3 of 11 d. Use of Audio and Video Recordings  
Video recordings of intervention sessions led by [CONTACT_225744]. These recordings will be destroyed once no longer needed for clinical supervision/ongoing training purposes. All re cordings will be destroyed before 
the study ends. 
 
e. Alternative Procedures or Courses of Treatment  
The procedures and treatment offered by [CONTACT_225745]. 
 
f. Will it be possible to continue the more (most) appropriate therapy for the 
participant(s) after the conclusion of the study?  
Therapy options (in the form of behavioral or psychosocial interventions ) will be offered to  
participants at the conclusion of the study, if indicated, including referrals to both in -clinic and 
external services.  
g. Study Endpoint(s)  
3-month (proximal endpoint ), 6-month (primary endpoint ), and 12- month (distal endpoint) follow -
ups. Endpoints were selected based on prior evaluations of similar interventions for youth with T1D showed effects at [ADDRESS_271378] Experimental and/or Clinical Findings  
Less than 1 out of every 4 adolescents with type 1 diabetes (T1D) meets the American Diabetes 
Association (ADA ) guidelines for target hemoglobin A1c, a common indicator of glycemic 
control. These deteriorations in glycemic control during adolescence can persist into adulthood. 
Family -based interventions are empi[INVESTIGATOR_225725], altho ugh 
behavioral health services are rarely included in diabetes care. Despi[INVESTIGATOR_225726], a minority of diabetes clinics offer any behavioral health services and less than 
[ADDRESS_271379]. Lack of behavioral hea lth providers who specialize in diabetes as 
well as institutional/economic constraints serve as barriers toward more integrated models of care, 
enhancing the need for intervention options that require limited resources. The current study seeks 
to address t hat need by [CONTACT_225746] -based family intervention to be optimized and 
integrated within real- world clinic care for adolescents with T1D and their parents.  
b. Findings from Past Animal Experiments 
None. 
4. PARTICIPANT POPULATION  
a. Planned Enrollment  

5/11/21  Page 4 of 11 The target enrollment will be 165 families (165 adolescents and 165 caregivers). 
Potential participants will be recruited through the Division of Pediatric Endocrinology 
and Diabetes at Stanford, the Stanford Diabetes Research Center's clinical registry, and 
online email listervs. Inclusion criteria are: 1) T1D diagnosis according to ADA criteria 
for at least 6 months, 2) ages 12 -19, and 3) participation of at least one cohabitating 
parent/caregiver. The age range was chosen due to evidence that diabetes management problems first arise between the ages of [ADDRESS_271380] greater autonomy can 
compromise self -management and glycemic control among adolescents with T1D. Less 
than 1 out of every 4 adolescents with type 1 diabetes (T1D) meets the American 
Diabetes Association (ADA) guidelines for target hemoglobin A1c, a common indicator of glycemic control. These deteriorations in glycemic control during adolescence can 
persist into  adulthood. Family -based interventions are empi[INVESTIGATOR_225727], although behavioral health services are rarely included in diabetes care. The current study seeks to identify ways to offset risks among adolescents.  
 
d. Rationale for Exclusion of Certain Populations  
Women, minorities, and children will be included.  
e. Stanford Populations  
None. 
f. Healthy Volunteers  
None. 
g. Recruitment Details  

5/11/[ADDRESS_271381] 
Diabetes Research Center's clinical registry and similar IRB approved emai l lists 
compromised of individuals who requested to be contact[CONTACT_225747], as well as online email listervs, and social media.  
In-clinic recruitment will consist of posting flyers in clinic, including exam rooms, waiting room, and hallways. The research team will recruit with the flyers and provide 
assistance with completing the online screening and informed consent when possible. 
Clinic staff will also be provided with copi[INVESTIGATOR_225728]. Stanford pediatric diabetes clinics are a common venue for research and 
patients are made aware that they participation or decision not to participate in  research 
will in no way compromise the services they receive there and that participation can be withdrawn at any time without any penalty or negative impact to the services that they 
receive.  
Potential participants will also be contact[CONTACT_225748], including the Stanford Diabetes Research Center's clinical 
registry (in which subjects have already consented to be recruited for research studi es). 
Stanford Diabetes Research Center's clinical registry is compromised of individuals who have expressed interest in participating in research and have voluntarily included their 
name [CONTACT_225755][CONTACT_225749] s. More 
information on the SDRC registry can be found at: https://sdrc.stanford.edu/clinical -
research -registry. Participants will also be recruited through online flyers sent out through 
established diabetes-related listervs run by [CONTACT_225750]. If/when eligibility criteria are revised, a re-send recruitment email (see Section 16) will be sent to again 
across listervs to clarify that interested potential participants who were previously 
ineligible have an opportunity to complete the screening agai n as they may now be 
eligible.  
The IRB-approved recruitment flyer and email will also be circulated through online 
websites, forums newsletters, emails listervs, and social media pages (primarily run by 
[CONTACT_225751]) and shared with diabetes providers and 
clinics within and outside of Stanford. These online avenues are often used to disseminate 
information to families of youth with type 1 diabetes offering various information and 
resources, including opportunities to participate in studies similar to the current study.  
 
h. Eligibility Criteria  
i. Inclusion Criteria  
Inclusion criteria are: 1 ) type 1 diabetes ( T1D) diagnosis according to ADA criteria for at least 6 
months, 2) ages 12 -19, and 3 ) participation of at least one cohabitating parent/caregiver. The age 
range was chosen due to evidence that diabetes management problems first arise between the ages 
of 11 and 18 years.  
ii. Exclusion Criteria  
Exclusion criteria will be lack of access to a smartphone or Wi -Fi via computer, restricted English 
proficiency, and pervasive developmental, cognitive, or psychiatric limitations that compromise participation in the intervention sessions and study. Glucos e monitors will be provided to 
5/11/21  Page 6 of 11 participants who are not already using these devices such that device use will not be a criterion of 
eligibility or exclusion.  
i. Screening Procedures  
Eligibility will be determined based on a screening survey completed through RedCap prior to informed consent and enrollment. 
 
j. Participation in Multiple Protocols  
Both verbal and written information on consent (and assent ) will be obtained by [CONTACT_225752]/or PI [INVESTIGATOR_225729]. 
Individuals who are not proficient in English or have any impairment in communication that might 
compromise informed consent/assent will be excluded from the study.  
k. Payments to Participants  
We will enroll 330 participants (165 adolescents with type 1 diabetes and their 165 caregivers ). 
Participants will be asked to participate in a 6 -session family -based intervention delivered via the 
internet, complete online surveys, provide glucose monitoring data either via continuous glucose 
monitors (CGMs ) that the have already been using prior to enrollment or blinded CGMs provided 
by [CONTACT_1758], and provide A1C test results that will be collected via chart review or from 
participants sharing their test results at baseline, 6 -month, and 12- month follow -up. W e will 
compensate each parent and each adolescent participant with a total of $  worth of gift cards for 
complete data collection. Graduated incentives are provided at each time point:  
  Baseline = $  
  First intermediate survey = $  
  Second intermediate survey = $   
  Third intermediate survey = $  
  3-month follow -up = $  
  6-month follow -up = $  
  12-month follow -up = $   
l. Costs to Participants 
None. 
m. Planned Duration of the Study  
The probable duration of the entire study is 4.5 years. We anticipate screening will require 5 
minutes, recruitment of all 165 participants can take up to 3 years, and activate participation in the 
study will require approximately 12 months. Each participa nt will spend 8 hours total on study 
participation and analysis of participant data will require approximately 1 year. Surveys will 
require approximately 30 minutes each to complete and each intervention sessions for the 
intervention group will require approximately 10 -20 minutes each.  
5. RISKS 
a. Potential Risks  
i. Investigational devices  

5/11/21  Page 7 of 11 None.  
ii. Investigational drugs 
None.  
iii. Commercially available drugs, biologics, reagents or chemicals  
None.   
iv. Procedures 
Data Collection: Self -reported survey will be kept confidential and collected online via secure 
REDCap database system. There are no known psychological risks to subjects completing self -
report subjective rating scales or participating in the intervention sessions. However, the survey 
and intervention may contain items or questions that make the subjects feel uncomfortable in that 
they ask about their physical and psychological health and feelings/emotions. Subjects will be 
informed that any items on questi onnaires or topi[INVESTIGATOR_225730]. Further, [CONTACT_214645] (PI) is a licensed psychologist 
who will be available to participants to address any potential discomfort or risks that may arise, 
assess, and triage as appropriate. If any discomfort or adverse events arise with continuous glucose 
monitor use, our research sta ff including [CONTACT_225756] will be available to assist and assure that 
the appropriate medical services are received to address the issue, as well as minimize risk in general. 
 
Intervention: Engaging in the intervention modules carries minimal risk for emotional discomfort or stress. Subjects will have the option of not participating in conversations or exercises in the intervention modules that cause them any discomfort. They wi ll also be free to withdraw from 
participating in the intervention and/or overall study at any time. All intervention modules will be 
carried out by [INVESTIGATOR_124]. Wong, a licensed clinical psychologist (license #[ZIP_CODE]) or a clinically trained 
interventionist who will be trained and supervised by [INVESTIGATOR_124]. Wong. Adolescent and caregiver 
participants will be advised of their rights to withdraw from the intervention at any time without 
penalty or consequence on their receipt of f uture health care services at Stanford University's 
Lucile Packard Children's Hospi[INVESTIGATOR_225731]. 
 
Protections Against Risk. [CONTACT_214645] and all research staff have completed rigorous training in the 
protection of human subjects, including CITI training. The plan for protecting privacy and 
confidentiality recognizes that the protection of privacy in studie s involving sensitive data is of 
utmost importance. We will attempt to do this in several ways. The PI [INVESTIGATOR_225732], benefits, and risks of the project to the subjects, and 
offer them an opportunity to ask questions and/or decline participation. The voluntary and 
confidential nature of the research, as well as limits to confidentiality, will be highlighted during informed consent process. Study participation will not interfere with clinical care and all patients 
have standard access to the treatment team on a routine ( clinical care ) and emergency basis. All 
responses to interview items will be given by [CONTACT_225753]. Survey data collection will only 
occur through tools and resources that have acceptable security features. We will minimize all communications that involve names or  other identifying information. All clinically -relevant and 
study information will be kept in locked files in locked offices or password protected files. Our research staff including [CONTACT_225756] will be available to assist and assure that the appropriat e 
medical services are received to address any issues with glucose monitoring, as well as minimize risk of issues related to device use. 
 
The participants will send the A1c test kits with their samples to the Advanced Research and 
Diagnostic Laboratory (ARDL ) at the University of Minnesota where it will be processed and the 
results will be sent securely without any identifiers to the study team.   
5/11/[ADDRESS_271382]. In all datasets we will use ID n umbers only. A separate dataset 
linking names with ID numbers will be accessible only to authorized study personnel under the direction of the PI.  
v. Radioisotopes/radiation-producing machines  
None.  
vi. Physical well-being  
None.  
vii. Psych ological  well-being 
Data Collection: Self -reported survey will be kept confidential and collected online via secure 
REDCap database system. There are no known psychological risks to subjects completing self -
report subjective rating scales or participating in intervention sess ions. However, the surveys and 
intervention topi[INVESTIGATOR_225733]/emotions. Subjects will be informed that any items on qu estionnaires or topi[INVESTIGATOR_225730]. Further, [CONTACT_214645] (PI) is a licensed psychologist 
who will be available to participants during data collection and will be facilitated the intervention 
in order to address any potential discomfort or risks that may arise, assess, and triage as 
appropriate. 
 
Intervention: Engaging in the intervention modules carries minimal risk for emotional discomfort 
or stress. Subjects will have the option of not participating in conversations or exercises in the 
intervention modules that cause them any discomfort. They wi ll also be free to withdraw from 
participating in the intervention and/or overall study at any time. All intervention modules will be 
carried out by [INVESTIGATOR_124]. Wong, a licensed clinical psychologist (license #[ZIP_CODE]) . Adolescent and 
caregiver participants will be advised of their rights to withdraw from the intervention at any time 
without penalty or consequence on their receipt of future health care services at Stanford 
University's Lucile Packard Children's Hospi[INVESTIGATOR_225734]. Protections Against Risk. [CONTACT_206650] has completed and will maintain rigorous training in the protection of human subjects, 
including CITI training. The plan for protecting privacy and confidentiality recognizes that the 
protection of  privacy in studies involving sensitive data is of utmost importance. We will attempt 
to do this in several ways. The PI [INVESTIGATOR_225735], benefits, and risks of the project to the subjects, and off er them an opportunity to ask 
questions and/or decline participation. The voluntary and confidential nature of the research, as 
well as limits to confidentiality, will be highlighted during informed consent process. Study 
participation will not interfere w ith clinical care and all patients have standard access to the 
treatment team on a routine ( clinical care ) and emergency basis. All responses to interview items 
will be given by [CONTACT_225753]. Survey data collection will only occur through tools and resources that have acceptable security features. We will minimize all communications that 
involve names or  other identifying information. All clinically -relevant and study information will 
be kept in locked files in locked offices or password protected files. 
 
All recordings of intervention sessions will be saved on a password- protected secure server. 
Information about subjects will not be accessible to any nonauthorized study personnel without the written consent of the subject. In all datasets we will use ID n umbers only. A separate dataset 
linking names with ID numbers will be accessible only to authorized study personnel under the 
direction of the PI. 
 
5/11/[ADDRESS_271383] to the subjects,  and offer them an opportunity to ask questions and/or decline participation. 
The voluntary and confidential nature of the research, as well as limits to confidentiality, will be 
highlighted during informed consent process. Study participation will not int erfere with clinical 
care and all patients have standard access to the treatment team on a routine (clinical care ) and 
emergency basis. All responses to interview items will be given by [CONTACT_225753]. Survey data 
collection will only occur through tools and resources that have acceptable security features. We 
will minimize all communications that involve names or  other identifying information. All 
clinically -relevant and study information will be kept in locked files in locked offices or password 
protected files. 
 
All recordings of intervention sessions will be saved on a password- protected secure server. 
Information about subjects will not be accessible to any nonauthorized study personnel without the 
written consent of the subject. In all datasets we will use ID n umbers only. A separate dataset 
linking names with ID numbers will be accessible only to authorized study personnel under the 
direction of the PI.  
d. Study Conclusion 
The study will end after 4.5 years. Participation will end one year after baseline data collection completion. No adverse events are anticipated. 
 
e. Data Safety Monitoring Plan (DSMC)  
i. Data and/or events subject to review 
We will review CGM data for wide and dangerous fluctuations in glucose levels, and 
report to the study participant and clinical team (if acceptable to study participant).  
ii. Person(s) responsible for Data and Safety Monitoring 
[CONTACT_225757] is responsible for ongoing monitoring and [CONTACT_225758] will 
serve as Safety Monitor.  
5/11/21  Page 10 of 11 iii. Frequency of DSMB meetings  
During the course of the trial, data will be reviewed monthly for completeness and 
accuracy (all data points fall within the possible range for each measure), with 
guidance from the mentorship team. In addition, bi -weekly reviews will examine 
occurrence of  adverse events and whether participants are satisfied with their 
participation.  
Because this study involves randomization and interventions associated with diabetes 
management, but because the study itself is not masked and is low risk, the PI [INVESTIGATOR_225736] (rather 
than a Data Safety and Monitoring Board). The Safety Monitor will be informed of 
all serious adverse events and any unanticipated adverse device events that occur during the study and will review compi[INVESTIGATOR_225737].  
iv. Specific triggers or stoppi[INVESTIGATOR_225738]/benefit ratio of the study and whether 
modifications to the protocol and consent forms are required.  Specific triggers 
include any indication through data collection or participant interactions that indicate severe risk, such as indications of diabetic ketoacidosis or suicidality. These issues 
are rare but our team will be trained in identifying early si gns to immediately inform 
PI [CONTACT_156869] w hether reporting, stoppi[INVESTIGATOR_007], and/or other actions must be taken.  
v. DSMB Reporting  
The PI [INVESTIGATOR_225739]. The Safety 
Monitor will be informed of all serious adverse events and any unanticipated adverse 
device events that occur during the study and will review compi[INVESTIGATOR_225740].  Unanticipated problems to be assessed include 
adverse events, deviations from the study protocol, problems with informed consent, and conf identiality violations.  
vi. Will the Protocol Director be the only monitoring entity? ( No) 
[CONTACT_225757] (PI) will primarily be responsible for monitoring though the project 
research coordinator will be trained in monitoring and [CONTACT_225759] will be consulted as 
needed.  
vii. Will a board, committee, or safety monitor be responsible for study monitoring? ( No) 
The Safety Monitor will be involved, as needed, in monitoring but will not be responsible for monitoring.  
 
f. Risks to Special Po pulations  
Benefits a ) Describe the potential benefit (s) to be gained by [CONTACT_225754], etc. This study presents no greater 
than minimal risk, given that all the procedures are no more invasive or risky than standard 
5/11/[ADDRESS_271384] (HIPAA)  and privacy policies of Stanford University, Stanford 
Health Care, and Stanford Childrenâ€™s Health.  